https://www.cancer.gov.co/centro-investigacion/nuestros-investigadores/pablo-moreno-acosta/publicaciones

oct 19, 2021 12:58

Publicaciones

miércoles, 03 de marzo de 2021

  • Moreno-Acosta P, Molano M, Morales N, Acosta J, González-Prieto C, Mayorga D, Buitrago L, Gamboa O, Mejía JC, Castro J, Romero-Rojas A, Espenel S, Murray GI, Garland S, Vallard A, Magné N. hTERT Protein Expression in Cytoplasm Nucleus its Association with HPV Infection in Patients with cervical cancer. Cancer Genomics & Proteomics September 2020, 17 (5) 615-625.
  • Pablo Moreno-Acosta, Alfredo Romero-Rojas, Nicolas Vial, Antonio Huertas, Jinneth Acosta, Diana Mayorga, Schyrly Carrillo, Monica Molano, Oscar Gamboa, Martha Cotes, Camila Casadiego, Alexis Vallard, Nicolas Magne.  Persistent High-Risk HPV Infection Molecular Changes Related to the Development of Cervical Cancer. Case Rep Obstet Gynecol 2020 Jul 23;2020:6806857. doi: 10.1155/2020/6806857. Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472445/pdf/cgp-17-615.pdf 
  • Moreno-Acosta P. et al. Potential Biomarkers for Personalized Radiation Therapy for Patients with Uterine Cervical Cancer. In: Farghaly S. (eds) Uterine Cervical Cancer. Springer, Cham. 2019. Link:
  • htps://www.researchgate.net/publication/330329631_Potential_Biomarkers_for_Personalized_Radiation_Therapy_for_Patients_with_Uterine_Cervical_Cancer  
  • Mónica Molano, Oscar Buitrago, Pablo Moreno-Acosta, Nubia Munoz. Follow‑up study of HPV58 variants in women with incident HPV58 infection from a Colombian cohort. Oncology Letters, 2018, 16(2). DOI: 10.3892/ol.2018.8928
  •  Espenel S, Garcia MA, Trone JC, Guillaume E, Harris A, Rehailia-Blanchard A, He MY, Ouni S, Vallard A, Rancoule C, Ben Mrad M, Chauleur C, De Laroche G, Guy JB, Moreno-Acosta P, Magné From IB2 to IIIB locally advanced cervical cancers: report of a ten-year experience. N. Radiat Oncol. 2018;13(1):50.
  • Moreno-Acosta P, Vallard A, Carrillo S, Gamboa O, Romero-Rojas A, Molano M, Acosta J, Mayorga D, Rancoule C, Garcia MA, Cotes Mestre M, Magné N. Biomarkers of resistance to radiation therapy: a prospective study in cervical carcinoma. Radiat Oncol. 2017; 12(1):120.Link: https://ro-journal.biomedcentral.com/articles/10.1186/s13014-017-0856-2
  • Moreno-Acosta P, Vallard A, Molano M, Huertas A, Gamboa O, Cotes M, Romero-Rojas A, Rancoule C, Magné N. HPV-16 variants’ impact on uterine cervical cancer response to radiotherapy: A descriptive pilot study. Cancer Radiother. 2017; 21(2):104-108. 
  • Link: https://www.sciencedirect.com/science/article/abs/pii/S1278321817300410?via=ihub  
  • Link: https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC5796580&blobtype=pdf 
  • Molano M, Moreno-Acosta P, Morales N, Burgos M, Buitrago L, Gamboa O, Alvarez R, Garland SM, Tabrizi SN, Steenbergen RD, Mejía JC. Association Type-specific HPV Infections hTERT DNA Methylation in Patients with Invasive Cervical Cancer. Cancer Genomics Proteomics. 2016 11-12;13(6):483-491.Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5219922/pdf/cgp-13-483.pdf
  • Pablo Moreno-Acosta,Schyrly Carrillo, Oscar Gamboa, Alfredo Romero-Rojas, Jinneth Acosta, Monica Molano, Joseph Balart-Serra, Martha Cotes, Chloé Rancoule, Nicolas Magné. Novel predictive biomarkers for cervical cancer prognosis. Mol Clin Oncol. 2016; 5(6): 792–796. DOI: 10.3892/mco.2016.1055. 
  • Miryam Puerto de Amaya, Pablo Moreno-Acosta, Martha Mora, Carlos, Pérez. Citología convencional y en base líquida en muestra compartida de tomas cervicouterinas. Revista Repertorio de Medicina y Cirugía, 2015, 24(1):41-46. DOI: 10.31260/RepertMedCir.v24.n1.2015.652
  • Moreno-Acosta P, Romero-Rojas A, Huertas A, Mayorga D, Morales N, Acosta J, Gamboa O, Magne N, Molano M. Diagnosis molecular targeting for individualized treatment of patients with pre-neoplastic lesions locally advanced cervical cancer. European Journal of Cancer. 2014; 50(6 Suppl), 119. Abstract. Link: https://www.sciencedirect.com/science/article/abs/pii/S0959804914704952 
  • Moreno-Acosta P, Romero-Rojas A, Carrillo S, Gamboa O, Acosta J, Balart-Serra J, Magne N. GLUT1 hemoglobin levels: Hypoxic markers of treatment response in patients with locally advanced cervical cancer. Molecular Cancer Therapeutics. 2013; 12(11 Suppl). Abstract. Link: https://mct.aacrjournals.org/content/12/11_Supplement/C39 
  • Moreno-Acosta P, Gamboa O, Sánchez de Gómez M, Diaz GD, Romero A, Balart-Serra J, Conrado Z, Levy A, Chargari C, Magne N.  IGF1R Gene Expression as a Predictive Marker of Response to Ionizing Radiation for Patients with Locally Advanced HPV16- positive Cervical Cancer. Anticancer Research 2012; 32: 4319-4326. Link: https://ar.iiarjournals.org/content/anticanres/32/10/4319.full.pdf 
Instituto Nacional de Cancerología
Empresa social del estado
  • Sede principal
  • Dirección: Calle 1 No. 9 -85 Bogotá DC, Colombia
  • Código postal: 111511-110411001
  • Horario de atención: Lunes a Viernes de 7:00 a.m. a 4:00 p.m. en jornada continua
  • Teléfono conmutador: (601) 3905012
  • Teléfono resto del país: 01 8000 414414
  • Correo notificaciones judiciales: [email protected]